StageZero Life Sciences's total inventories for the quarter that ended in Sep. 2024 was C$0.07 Mil. StageZero Life Sciences's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was C$0.05 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. StageZero Life Sciences's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was C$-0.13.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
StageZero Life Sciences's Days Inventory for the
three
months ended in Sep. 2024 was 6.03.
Inventory Turnover measures how fast the company turns over its inventory within a year.
StageZero Life Sciences's Inventory Turnover for the quarter that ended in Sep. 2024 was 15.14.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
StageZero Life Sciences's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.08.
StageZero Life Sciences (TSXV:SZLS.H) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
StageZero Life Sciences's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
StageZero Life Sciences's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
StageZero Life Sciences Total Inventories Related Terms
StageZero Life Sciences Total Inventories Historical Data
* Premium members only.
The historical data trend for StageZero Life Sciences's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StageZero Life Sciences Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
StageZero Life Sciences (TSXV:SZLS.H) has a Total Inventories of C$0.07 Mil as of Sep. 2024. The total amount of inventory as recorded on a company's balance sheet. View historical data for StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' Total Inventories too high?
StageZero Life Sciences' current Total Inventories is C$0.07 Mil. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' Total Inventories compare to IDTA and TTOO?
StageZero Life Sciences' Total Inventories of C$0.07 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for StageZero Life Sciences and its competitors. StageZero Life Sciences's current Total Inventories is C$0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (TSXV:SZLS.H) has a current Total Inventories of C$0.07 Mil. The current Total Inventories is C$0.07 Mil. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For StageZero Life Sciences (TSXV:SZLS.H), the current Total Inventories is C$0.07 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score
Get the complete analysis for TSXV:SZLS.H
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SZLS.H has been successfully added to your 
